Search Bar & Filters
Found 2 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the safety and effectiveness of EIK1001 combined with Pembrolizumab compared to a placebo plus Pembrolizumab as the first treatment for patients with advanced melanoma. This is a multicenter, randomized, double-blind phase 23 trial that includes dose optimization and expansion parts to assess these therapies. The trial is sponsored by Eikon Therapeutics and targets patients eligible for standard Pembrolizumab therapy. Participants are randomly assigned to one of three groups one receiving a placebo with Pembrolizumab, another receiving a selected dose of EIK1001 plus Pembrolizumab, and a third receiving a different dose of EIK1001 plus Pembrolizumab. EIK1001 is a drug that activates specific immune receptors, and Pembrolizumab is an immune checkpoint inhibitor. The study includes dose optimization in the early phase and expands to larger groups for further evaluation. During the study, participants will undergo regular assessments including imaging scans to measure tumor response, blood tests to monitor organ function, and evaluations of any side effects. Researchers will measure outcomes such as progression-free survival, overall survival, and objective tumor response over a period of up to five years. Safety and adverse events will be closely monitored, particularly during the dose optimization phase. Participants may be followed for up to five years to track long-term effects and treatment outcomes.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of a drug called ONL1204 in people aged 55 and older who have geographic atrophy GA related to age-related macular degeneration AMD. GA associated with AMD is a leading cause of vision loss and blindness globally, linked to aging and other risk factors. This phase 2 study aims to understand how different doses and treatment schedules of ONL1204 affect this condition. Participants will receive one of several treatments ONL1204 injections at two dose levels 100 or 200 micrograms every 12 weeks, ONL1204 200 micrograms every 24 weeks, sham injections every 12 or 24 weeks, or monthly injections of avacincaptad pegol. All injections are given into the eye intravitreal. This randomized, double-masked trial compares these different groups over a period of 48 weeks. During the study, participants will have regular visits for eye exams, imaging, and vision tests to monitor their condition and treatment effects. Researchers will track safety and efficacy outcomes throughout the 48 weeks. Participants must meet specific vision and eye health criteria to join, and safety monitoring will continue throughout the treatment period to ensure participant well-being.